These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32682941)

  • 1. Assessment of nicotine release from nicotine-loaded chitosan nanoparticles dry powder inhaler formulations via locomotor activity of C57BL/6 mice.
    Wang H; Holgate J; Bartlett S; Islam N
    Eur J Pharm Biopharm; 2020 Sep; 154():175-185. PubMed ID: 32682941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotine hydrogen tartrate loaded chitosan nanoparticles: Formulation, characterization and in vitro delivery from dry powder inhaler formulation.
    Wang H; George G; Bartlett S; Gao C; Islam N
    Eur J Pharm Biopharm; 2017 Apr; 113():118-131. PubMed ID: 28088005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Chemical Conjugation of l-Leucine to Chitosan on Dispersibility and Controlled Release of Drug from a Nanoparticulate Dry Powder Inhaler Formulation.
    Muhsin MD; George G; Beagley K; Ferro V; Wang H; Islam N
    Mol Pharm; 2016 May; 13(5):1455-66. PubMed ID: 26998555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
    Islam N; Richard D
    Curr Cancer Drug Targets; 2019; 19(3):162-178. PubMed ID: 29793407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in device and formulation technologies for pulmonary drug delivery.
    Chan JG; Wong J; Zhou QT; Leung SS; Chan HK
    AAPS PharmSciTech; 2014 Aug; 15(4):882-97. PubMed ID: 24728868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice.
    Vartiainen V; Raula J; Bimbo LM; Viinamäki J; Backman JT; Ugur N; Kauppinen E; Sutinen E; Joensuu E; Koli K; Myllärniemi M
    Int J Pharm; 2018 Jun; 544(1):121-128. PubMed ID: 29655797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline.
    Rawal T; Patel S; Butani S
    Eur J Pharm Sci; 2018 Nov; 124():273-287. PubMed ID: 30176365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative carriers in dry powder inhaler formulations.
    Rahimpour Y; Kouhsoltani M; Hamishehkar H
    Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an inhalable, stimuli-responsive particulate system for delivery to deep lung tissue.
    Abbas Y; Azzazy HM; Tammam S; Lamprecht A; Ali ME; Schmidt A; Sollazzo S; Mathur S
    Colloids Surf B Biointerfaces; 2016 Oct; 146():19-30. PubMed ID: 27244047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technological and practical challenges of dry powder inhalers and formulations.
    Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
    Adv Drug Deliv Rev; 2014 Aug; 75():18-31. PubMed ID: 24735675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Aerosolization Using Computational Fluid Dynamics in a Pediatric Air-Jet Dry Powder Inhaler.
    Bass K; Farkas D; Longest W
    AAPS PharmSciTech; 2019 Nov; 20(8):329. PubMed ID: 31676991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.
    Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Patzlaff A; Weimann B
    J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):156-163. PubMed ID: 30848695
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of an inhalation chamber and a dry powder inhaler device for administration of pulmonary medication in animal model.
    Sinha B; Mukherjee B
    Drug Dev Ind Pharm; 2012 Feb; 38(2):171-9. PubMed ID: 21721851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalable nanoparticulate powders for respiratory delivery.
    Muralidharan P; Malapit M; Mallory E; Hayes D; Mansour HM
    Nanomedicine; 2015 Jul; 11(5):1189-99. PubMed ID: 25659645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.